Session I: Chronic Myeloid Leukemia

CML: State of the Art Update
Jorge Cortés, MD
The University of Texas MD Anderson Cancer Center,
Houston, Texas, USA

ELN v NCCN: Do We Have Consensus?
Charles A. Schiffer, MD
Karmanos Cancer Institute,
Wayne State University School of Medicine,
Detroit, Michigan, USA

Case Studies in TFR
Delphine Rea, MD, PhD
Saint Louis Hospital
Paris, France

When Second Generation TKIs Fail
Jerald P. Radich, MD
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, Washington, USA

DEBATE: Second Generation TKIs Are The Preferred Frontline Treatment Option for All CML Patients Where TFR Is The Main Goal – Pro
Giuseppe Saglio, MD
The University of Turin
and San Luigi Hospital, Turin, Italy

DEBATE: Second Generation TKIs Are The Preferred Frontline Treatment Option for All CML Patients Where TFR Is The Main Goal – Con
Jane F. Apperley, MBChB, MD, FRCP, FRCPath
Hammersmith Hospital London Imperial College
London, United Kingdom

Advanced Phase Disease: Current Management
Michael Deininger, MD, PhD
Huntsman Cancer Hospital
The University of Utah
Salt Lake City, Utah, USA

CML: Next Questions
Timothy P. Hughes, MD, FRACP, FRCPA
South Australian Health and
Medical Research Institute, Adelaide, Australia

Session II: Myelodysplastic Syndromes

What is New In MDS in 2018?
Valeria Santini, MD
University of Florence, Florence, Italy

Selecting the Right Lower Risk Patient For Stem Cell Transplantation
Uwe Platzbecker, MD
University Hospital Carl Gustav Carus
Dresden, Germany

Inherited Predisposition and Pediatric MDS
Marcin W. Wlodarski, MD, PhD
St. Jude Children’s Hospital
Memphis, Tennessee, USA

DEBATE: Should MDS Diagnosis Still Be Mainly Based on Morphology? Yes
Robert Paul Hasserjian, MD
Massachusetts General Hospital
Boston, Massachusetts, USA

DEBATE: Should MDS Diagnosis Still Be Mainly Based on Morphology? No
Lucy A. Godley, MD, PhD
The University of Chicago
Chicago, Illinois, USA

Improving Results with Hypomethylating Agents in MDS
Pierre Fenaux, MD, PhD
Hospital St. Louis, Paris, France

Problems Ahead in MDS: What Is Next?
Guillermo Garcia-Manero, MD
The University of Texas
MD Anderson Cancer Center, Houston, Texas, USA

Session III: Myeloproliferative Neoplasms

State of the Art Update: The Origins of MPN
Radek C. Skoda, MD
University Hospital Basel
Basel, Switzerland

Assessing Thrombotic Risk of ET and PV in the Genomic Era
Laura C. Michaelis, MD
Medical College of Wisconsin
Milwaukee, Wisconsin, USA

Rare Malignancy Topic: Primer on Advanced Mastocytosis
Robyn M. Scherber, MD
Mays Cancer Center at UT Health San Antonio MD
Anderson, San Antonio, Texas, USA

Will Mutations Affect Transplant Decisions in Myelofibrosis
H. Joachim Deeg, MD
Fred Hutchinson Cancer Research Center
University of Washington School of Medicine
Seattle, Washington, USA

Case Study: Accelerated MF
Srdan Verstovsek, MD, PhD
The University of Texas
MD Anderson Cancer Center, Houston, Texas, USA

Next Questions: Understanding Fibrotic and Leukemic Transformation of MPN
Radek C. Skoda, MD
University Hospital Basel
Basel, Switzerland

Session IV: Acute Lymphoblastic Leukemia

CART T Cell Therapy: CD19, CD22 and Beyond
Terry J. Fry, MD
Children’s Hospital Colorado
Aurora, Colorado, USA

MLL Leukemias: A Remaining Hurdle
Rob Pieters, MD, PhD
Princess Máxima Center for Pediatric Oncology
Utrecht, The Netherlands

Combining Molecular Genetics and Cytogenetics for Prognostication
Hervé Dombret, MD
Institut Universitaire d’Hématologie
Paris, France

Can MRD Monitoring Be Done Using Peripheral Blood?
Lori Muffly, MD
Stanford University Medical Center
Palo Alto, California, USA

T-ALL: Nelarabine In The Frontline; and What to Do About Relapse?
Daniel J. DeAngelo, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

Update on AYA ALL: Progress, Challenges and Next Steps
Wendy Stock, MD
The University of Chicago
Chicago, Illinois, USA

One Treatment For All in ALL: A Stratified
Treatment Approach for Patients 1-45 Years Old

Kjeld Schmiegelow, MD
Copenhagen University Hospital
Copenhagen, Denmark

Session V: Acute Myeloid Leukemia

AML: State of the Art Update
Harry P. Erba, MD, PhD
Duke University
Durham, North Carolina, USA

NGS at Diagnosis: Uses And Pitfalls
Christopher James Gibson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

Induction: Should We “GO” To FLAG-ida, etc?
Alan K. Burnett, MD
Formerly Cardiff University School of Medicine
Cardiff, United Kingdom

MRD: Is it a Thing in AML?
Gert Ossenkoppele, MD, PhD
VU University Medical Center
Amsterdam, The Netherlands

Immunotherapy in AML: Anything There?
Naval G. Daver, MD
The University of Texas
MD Anderson Cancer Center, Houston, Texas, USA

CAR-transduced T and NK cells In AML: Near or Far Away
Katy Rezvani, MD, PhD
The University of Texas
MD Anderson Cancer Center, Houston, Texas, USA

Debate: Use Gemtuzumab in Most AML Patients vs
Use Gemtuzumab in CBF Patients or Not at All? Pro

Roland B. Walter, MD, PhD
Fred Hutchinson Cancer Research Center
University of Washington School of Medicine
Seattle, Washington, USA

Debate: Use Gemtuzumab in Most AML Patients vs
Use Gemtuzumab in CBF Patients or Not at All? Con

Gail J. Roboz, MD
Weill Medical College of Cornell University
New York, New York, USA

AML: Next Questions
Richard Stone, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

Session VI: Multiple Myeloma

MM: State of the Art Update
Sagar Lonial, MD, FACP
Winship Cancer Institute of Emory University
Atlanta, Georgia, USA

How Does Genetics and MRD Impact Treatment or Doesn’t It?
Ajay K. Nooka, MD, MPH, FACP
Winship Cancer Institute of Emory University
Atlanta, Georgia, USA

New Targets in Relapsed And Refractory MM
Thomas G. Martin, MD
University of California San Francisco
San Francisco, California, USA

Management and Diagnosis of Amyloid: What is New?
Suzanne Lentzsch, MD, PhD
Columbia University and at
New York Presbyterian Hospital, New York, USA

Emerging Data on Management and Imaging of Myeloma Bone Disease
Meletios Dimopoulos, MD
University of Athens
Athens, Greece

What Will the Future Hold for Myeloma Treatment CARTs vs BiTES?
Robert Z. Orlowski, MD, PhD
The University of Texas
MD Anderson Cancer Center, Houston, Texas, USA

The Role of ASCT In The Era of Modern MM Therapy
Peter M. Voorhees, MD
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina, USA

MM: Next Questions
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
New York, New York, USA

Session VII: Hodgkin Lymphoma

Treatment of Newly Diagnosed HL
David J. Straus, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, USA

Treatment of Relapsed HL
Stephen M. Ansell, MD, PhD
Mayo Clinic, Rochester, Minnesota, USA

Session VIII: Non-Hodgkin Lymphoma

Biology of DLBCL
Laura Pasqualucci, MD
Columbia University, New York, New York, USA

What’s Next for First Line Therapy?
Thomas E. Witzig, MD
Mayo Clinic Rochester
Rochester, Minnesota, USA

Treatment of Relapsed DLBCL
Thomas E. Witzig, MD
Mayo Clinic Rochester
Rochester, Minnesota, USA

Marginal Zone Lymphoma
Emanuele Zucca, MD
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland

Treatment of Newly Diagnosed and Relapsed TCell Lymphoma
Steven M. Horwitz, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York, USA

New Approaches to the Management of CTCL
Pierluigi Porcu, MD
Jefferson Hospital, Sidney Kimmel Cancer Center,
Philadelphia, Pennsylvania, USA

Mantle Cell Lymphoma Biology
Elías Campo, MD
Hospital Clinic of the University of Barcelona
Barcelona, Spain

Management of Newly Diagnosed MCL
Simon Rule, MD
Derriford Hospital
Plymouth, United Kingdom

Management of Relapsed MCL
Luhua M. Wang, MD
The University of Texas
MD Anderson Cancer Center, Houston, Texas, USA

Management of Newly Diagnosed FL
Mathias J. Rummel, MD, PhD
Justus-Liebig University-Hospital
Giessen, Germany

Relapsed Follicular Lymphoma
Nathan H. Fowler, MD
The University of Texas
MD Anderson Cancer Center, Houston, Texas, USA

How I Treat Double Hit Lymphoma
Kieron M. Dunleavy, MD
George Washington University Cancer Center
Washington, DC, USA

Advances in the Treatment of PCNSL
Christopher J. Melani, MD
National Cancer Institute
Bethesda, Maryland, USA

Session IX: Chronic Lymphocytic Leukemia

CLL: State of the Art Update
Florence Cymbalista, MD, PhD
Hôpital Avicenne, Bobigny, France

Evolving First-line Treatment for Patients with CLL
Nitin Jain, MD
The University of Texas
MD Anderson Cancer Center, Houston, Texas, USA

Debate: CIT is Over? Yes
Philip Thompson, MB, BS
The University of Texas
MD Anderson Cancer Center, Houston, Texas, USA

DEBATE: CIT is Over? No
Barbara F. Eichhorst, MD
University of Cologne
Cologne, Germany

Sequencing of Targeted Therapy
Anthony R. Mato, MD, MSCE
Memorial Sloan-Kettering Cancer Center
New York, New York, USA

CLL: Next Questions
Florence Cymbalista, MD, PhD
Hôpital Avicenne, Bobigny, France

Session X: Research Topics

Single-cell Analysis to Assess Cross-Priming of Tumor-Reactive T Cells
Joshua Brody, MD
Mount Sinai School of Medicine
New York, New York, USA

Lung Injury After Allogeneic Hematopoietic Cell Transplantation
Gerhard C. Hildebrandt, MD, FACP
University of Kentucky
Lexington, Kentucky, USA

Targeting Leukemia Metabolism
Jing Chen, PhD
Winship Cancer Institute of Emory University
Atlanta, Georgia, USA

Hematopoietic Stem Cell Rejuvenation: Aging Alters
the Epigenetic Asymmetry of Stem Cell Divisions

Maria Carolina Florian, PhD
Ulm University, Ulm, Germany

Share this story, choose your platform!